Siemens Healthcare Diagnostics has identified that in certain disease states, where significantly elevated m-protein (paraprotein) levels occur, there is a potential for interference in inorganic phosphorus assay from specific monoclonal m-proteins resulting in falsely elevated results. The paraprotein interference issue is not reagent lot-specific and the issue is limited to patients with monoclonal gammopathies. Paraproteins may precipitate after reagent addition and may product falsely elevated IP results or high absorbance flags (root cause). Quality control will not alert the user to the issue. The ADVIA Chemistry Inorganic Phosphorus (IP) and Inorganic Phosphorus Concentrated (IP_C) assays, and ATELLICA CH Inorganic Phosphorus (IP) assay instructions for use (IFUs) do not include limitations for paraprotein interference.